Enantiomeric pure β agonists, manufacturing and use as a medicament thereof
    31.
    发明授权
    Enantiomeric pure β agonists, manufacturing and use as a medicament thereof 失效
    对映体纯β激动剂,制造和用作其药物

    公开(公告)号:US07534789B2

    公开(公告)日:2009-05-19

    申请号:US11686565

    申请日:2007-03-15

    申请人: Uwe Ries Peter Sieger

    发明人: Uwe Ries Peter Sieger

    IPC分类号: C07D413/04 A61K31/538

    CPC分类号: C07D413/12

    摘要: The present invention relates to enantiomerically pure compounds of formula 1 wherein the groups m, n, B, X, R1, m and Ym− may have the meanings given in the claims and specification, methods for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

    摘要翻译: 本发明涉及对映异构体纯的式1化合物,其中m,n,B,X,R 1,m和Y m-基团可以具有权利要求书和说明书中给出的含义,制备它们的方法及其作为药物组合物的用途, 特别是用于治疗呼吸道疾病的药物组合物。

    Enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof
    32.
    发明授权
    Enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof 有权
    对映体纯β激动剂,制造和用作其药物

    公开(公告)号:US07939658B2

    公开(公告)日:2011-05-10

    申请号:US12419505

    申请日:2009-04-07

    申请人: Uwe Ries Peter Sieger

    发明人: Uwe Ries Peter Sieger

    IPC分类号: C07D413/04 A61K31/538

    CPC分类号: C07D413/12

    摘要: The present invention relates to enantiomerically pure compounds of formula 1 wherein the groups m, n, B, X, R1, m and Ym− may have the meanings given in the claims and specification, methods for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

    摘要翻译: 本发明涉及对映体纯的式1化合物,其中m,n,B,X,R 1,m和Y m-基团可以具有权利要求书和说明书中给出的含义,制备它们的方法及其作为药物组合物的用途, 特别是用于治疗呼吸道疾病的药物组合物。

    Production method
    33.
    发明授权
    Production method 有权
    生产方式

    公开(公告)号:US07696346B2

    公开(公告)日:2010-04-13

    申请号:US11840397

    申请日:2007-08-17

    IPC分类号: C07D401/04 C07D401/14

    摘要: The present invention relates to a process for preparing compounds of general formula I wherein R1 and R2 are defined as in claim 1, the pharmaceutically acceptable salts and the solvates thereof, which may be prepared starting from compounds of general formula II wherein R1 is defined as in claim 1.

    摘要翻译: 本发明涉及一种制备通式Ⅰ化合物的方法,其中R 1和R 2如权利要求1所定义,其药学上可接受的盐和溶剂化物,其可以从通式II的化合物制备,其中R1定义为 在权利要求1中。

    Crystalline compounds
    34.
    发明授权
    Crystalline compounds 有权
    结晶化合物

    公开(公告)号:US07638625B2

    公开(公告)日:2009-12-29

    申请号:US11734520

    申请日:2007-04-12

    IPC分类号: C07D491/04 C07D491/14

    CPC分类号: C07D401/14 C07D401/04

    摘要: The present invention relates to the new crystalline compounds A of general formula I wherein A1, A2, A3, X, Y1, Y2 and Y3 are defined as in claim 1, and which are present in the form of their physiologically acceptable salts with acids, the acids being selected from the group B comprising hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, benzenesulphonic acid, p-toluenesulphonic acid, maleic acid, succinic acid, fumaric acid, D-(−)-tartaric acid, L-(+)-tartaric acid, naphthalene-2-sulphonic acid and naphthalene-1,5-disulphonic acid, and the polymorphs, the corresponding solvates and hydrates thereof.

    摘要翻译: 本发明涉及通式Ⅰ的新的结晶化合物A,其中A1,A2,A3,X,Y1,Y2和Y3如权利要求1中所定义,并且以其与酸的生理上可接受的盐的形式存在, 选自乙酸,氢溴酸,硫酸,磷酸,苯磺酸,对甲苯磺酸,马来酸,琥珀酸,富马酸,D - ( - ) - 酒石酸,L-( +) - 酒石酸,萘-2-磺酸和萘-1,5-二磺酸,其多晶型物,相应的溶剂合物和水合物。